When The Cancer Genome Atlas (TCGA) launched in 2006, it was a huge moment for cancer research. The National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) had come together to deliver researchers a better understanding of the molecular basis of cancer through the application of genome analysis and sequencing technologies.
National Brain Tumor Society launched our Defeat GBM Research Collaborative in March of 2013 to great enthusiasm from both the patient and scientific communities. As our boldest strategic research initiative to-date, the Defeat GBM Research Collaborative aims to double the five-year survival rate of glioblastoma multiforme (GBM) patients in just five years.
Dr. David Louis, Pathologist-in-Chief at Massachusetts General Hospital (MGH) and Benjamin Castleman Professor of Pathology at Harvard Medical School, is an internationally recognized expert in brain tumor pathology and molecular genetics.